(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase : M.R. Jirousek, et al.; J. Med. Chem. 39, 2664 (1996) Abstract Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes: M.A. Cotter, et al.; Clin Sci (Lond) 103, 311 (2002) Abstract Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons: H. Kim, et al.; Diabetes 52, 2102 (2003) Abstract; Full Text Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation: S. Itoh, et al.; J. Biol. Chem. 280, 24135 (2005) Abstract; Full Text Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats: Y. Wu, et al.; J. Pharmacol. Sci. 101, 335 (2006) Abstract; Full Text Ruboxistaurin: C.A. Taulien & S.V. Joy; Drugs Today (Barc) 42, 577 (2006) Abstract Ruboxistaurin: LY 333531: Drugs R. D. 8, 193 (2007), (Review) Abstract Role of PKC and TGF-beta receptor in glucose-induced proliferation of smooth muscle cells: Y. Yasuda, et al; BBRC 281, 71 (2001) Abstract
|